Beijing Tiantan Biological Products Co., Ltd. (SHA:600161)
China
· Delayed Price · Currency is CNY 20.45
-0.40 (-1.92%)
Apr 22, 2025, 2:45 PM CST
SHA:600161 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 6,109 | 6,013 | 5,162 | 4,244 | 4,112 | 3,434 | Upgrade
|
| Other Revenue | 19.11 | 19.11 | 18.38 | 16.86 | - | 11.28 | Upgrade
|
| Revenue | 6,128 | 6,032 | 5,180 | 4,261 | 4,112 | 3,446 | Upgrade
|
| Revenue Growth (YoY) | 19.91% | 16.43% | 21.57% | 3.63% | 19.35% | 4.99% | Upgrade
|
| Cost of Revenue | 2,945 | 2,739 | 2,553 | 2,172 | 2,159 | 1,751 | Upgrade
|
| Gross Profit | 3,183 | 3,293 | 2,628 | 2,089 | 1,954 | 1,695 | Upgrade
|
| Selling, General & Admin | 614.41 | 614.41 | 739.98 | 627.83 | 599.41 | 491.34 | Upgrade
|
| Research & Development | 142.79 | 142.79 | 139.95 | 122.01 | 133.21 | 118.61 | Upgrade
|
| Other Operating Expenses | 53.92 | 53.92 | 42.36 | 44.92 | 47.06 | 36.06 | Upgrade
|
| Operating Expenses | 820.86 | 820.86 | 921.64 | 796.02 | 779.55 | 646.18 | Upgrade
|
| Operating Income | 2,362 | 2,472 | 1,706 | 1,293 | 1,174 | 1,049 | Upgrade
|
| Interest Expense | -5.12 | -5.12 | -3.65 | -2.41 | -3.09 | -2.98 | Upgrade
|
| Interest & Investment Income | 104.78 | 104.78 | 92.74 | 90.19 | 80.92 | 35.86 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.04 | -0.04 | 0 | 0.01 | -0 | -0.13 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.3 | -0.37 | -5.01 | -0.7 | -3.05 | -1.22 | Upgrade
|
| EBT Excluding Unusual Items | 2,461 | 2,571 | 1,790 | 1,380 | 1,249 | 1,080 | Upgrade
|
| Impairment of Goodwill | -45.99 | -45.99 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -7.33 | -7.33 | -1.04 | 13.55 | -0.3 | -0.62 | Upgrade
|
| Asset Writedown | -0.23 | -0.23 | -0.22 | -0.03 | -14.28 | -0.06 | Upgrade
|
| Other Unusual Items | 29.76 | 29.76 | 9.65 | 32.63 | 6.77 | 25.18 | Upgrade
|
| Pretax Income | 2,437 | 2,547 | 1,799 | 1,426 | 1,241 | 1,105 | Upgrade
|
| Income Tax Expense | 397.54 | 434.95 | 289.14 | 221.6 | 172.2 | 161.8 | Upgrade
|
| Earnings From Continuing Operations | 2,040 | 2,112 | 1,509 | 1,205 | 1,069 | 943.08 | Upgrade
|
| Minority Interest in Earnings | -563.1 | -563.1 | -399.57 | -323.76 | -308.8 | -304.07 | Upgrade
|
| Net Income | 1,477 | 1,549 | 1,110 | 880.92 | 760.01 | 639.01 | Upgrade
|
| Net Income to Common | 1,477 | 1,549 | 1,110 | 880.92 | 760.01 | 639.01 | Upgrade
|
| Net Income Growth | 26.79% | 39.58% | 25.99% | 15.91% | 18.94% | 4.57% | Upgrade
|
| Shares Outstanding (Basic) | 2,000 | 1,986 | 1,982 | 1,994 | 1,940 | 1,806 | Upgrade
|
| Shares Outstanding (Diluted) | 2,000 | 1,986 | 1,982 | 1,994 | 1,940 | 1,806 | Upgrade
|
| Shares Change (YoY) | 0.15% | 0.21% | -0.62% | 2.79% | 7.41% | 0.59% | Upgrade
|
| EPS (Basic) | 0.74 | 0.78 | 0.56 | 0.44 | 0.39 | 0.35 | Upgrade
|
| EPS (Diluted) | 0.74 | 0.78 | 0.56 | 0.44 | 0.39 | 0.35 | Upgrade
|
| EPS Growth | 26.59% | 39.29% | 26.78% | 12.77% | 10.73% | 3.95% | Upgrade
|
| Free Cash Flow | - | -247.63 | 1,316 | -228.02 | -151.35 | 93.2 | Upgrade
|
| Free Cash Flow Per Share | - | -0.13 | 0.66 | -0.11 | -0.08 | 0.05 | Upgrade
|
| Dividend Per Share | 0.100 | 0.100 | 0.125 | 0.042 | 0.069 | 0.069 | Upgrade
|
| Dividend Growth | -20.00% | -20.00% | 199.76% | -39.91% | - | 99.42% | Upgrade
|
| Gross Margin | 51.94% | 54.59% | 50.72% | 49.02% | 47.51% | 49.19% | Upgrade
|
| Operating Margin | 38.54% | 40.98% | 32.93% | 30.34% | 28.55% | 30.44% | Upgrade
|
| Profit Margin | 24.10% | 25.68% | 21.43% | 20.67% | 18.48% | 18.55% | Upgrade
|
| Free Cash Flow Margin | - | -4.11% | 25.40% | -5.35% | -3.68% | 2.71% | Upgrade
|
| EBITDA | 2,681 | 2,777 | 1,954 | 1,452 | 1,313 | 1,182 | Upgrade
|
| EBITDA Margin | 43.75% | 46.04% | 37.72% | 34.07% | 31.92% | 34.29% | Upgrade
|
| D&A For EBITDA | 319.35 | 305.12 | 248.17 | 158.74 | 138.65 | 132.75 | Upgrade
|
| EBIT | 2,362 | 2,472 | 1,706 | 1,293 | 1,174 | 1,049 | Upgrade
|
| EBIT Margin | 38.54% | 40.98% | 32.93% | 30.34% | 28.55% | 30.44% | Upgrade
|
| Effective Tax Rate | 16.31% | 17.08% | 16.08% | 15.54% | 13.88% | 14.64% | Upgrade
|
| Revenue as Reported | 6,032 | 6,032 | 5,180 | 4,261 | 4,112 | 3,446 | Upgrade
|
| Advertising Expenses | - | 1.89 | 1.63 | 5.26 | 6.35 | 7.41 | Upgrade
|
Updated Oct 25, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.